Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Nonhospitalized Patients

Journal of Clinical Microbiology

Volumn 42, Issue 3, 2004, Pages 1089-1094

  Rodríguez Baño, Jesús ^a   Navarro, Maria Dolores ^a   Romero, Luisa ^a   Martínez Martínez, Luis ^a,b   Muniain, Miguel A ^a   Perea, Evelio J ^a   Pérez Cano, Ramón ^a   Pascual, Alvaro ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PALINDROMIC DNA; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; ASYMPTOMATIC BACTERIURIA; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; CASE CONTROL STUDY; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; ISOELECTRIC FOCUSING; MALE; MULTIVARIATE ANALYSIS; NATURAL SELECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT INFECTION; REPETITIVE EXTRAGENIC PALINDROMIC SEQUENCE POLYMERASE CHAIN REACTION; RISK FACTOR; SPAIN; URINARY TRACT INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BASE SEQUENCE; BETA-LACTAMASES; DNA PRIMERS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; OUTPATIENTS; POLYMERASE CHAIN REACTION; RECURRENCE; SEASONS; SPAIN; SPUTUM;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; NEGIBACTERIA;

EID: 12144290133     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.3.1089-1094.2004     Document Type: Article

References (32)

1. Borer, A., J. Gilad, G. Menashe, N. Peled, K. Riesenberg, and F. Schlaeffer. 2002. Extended-spectrum beta-lactamase-producing Enterobacteriaceae strains in community-acquired bacteremia in Southern Israel. Med. Sci. Monit. 8:CR44-CR47. [Online.]
2. Bou, G., M. Cartelle, M. Tomas, D. Canle, F. Molina, R. Moure, J. M. Eiros, and A. Guerrero. 2002. Identification and broad dissemenation of the CTX-M-14 beta-lactamase in different Escherichia coli strains in the northwest areas of Spain. J. Clin. Microbiol. 40:4030-4036.
3. Bradford, P. A., C. Urban, A. Jaiswal, N. Mariano, B. A. Rasmussen, S. J. Projan, J. J. Rahal, and K. Bush. 1995. SHV-7, a novel cafotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob. Agents Chemother. 39:899-905.
4. Bradford, P. A. 2001. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951.
5. Bush, K., and S. B. Singer. 1989. Effective cooling allows sonication to be used for liberation of beta-lactamases from gram-negative bacteria. J. Antimicrob. Chemother. 24:82-84.
6. Charlson, M. E., P. Pompei, K. L. Ales, and C. R. MacKenzie. 1987. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383.
7. Coque, T. M., A. Oliver, J. C. Perez-Diaz, F. Baquero, and R. Canton. 2002. Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum beta-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob. Agents Chemother. 46:500-510.
8. Cormican, M., D. Morris, G. Corbett-Feeney, and J. Flynn. 1998. Extended-spectrum beta-lactamase production and fluoroquinolone resistance in pathogens associated with community-acquired urinary tract infection. Diagn. Microbiol. Infect. Dis. 32:317-319.
9. Daza, R., J. Gutierrez, and G. Piedrola. 2001. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int. J. Antimicrob. Agents 18:211-215.
10. Garner, J. S., W. R. Jarvis, T. G. Emori, T. C. Horan, and J. M. Hughes. 1988. CDC definitions for nosocomial infections. Am. J. Infect. Control 16:128-140.
11. Goldstein, F. W., and the Multicenter Study Group. 2000. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Eur. J. Clin. Microbiol. Infect. Dis. 19:112-117.
12. Harris, A. D., T. B. Karchmer, Y. Carmeli, and S. H. Samore. 2001. Methodological principles of case-control studies that analysed risk factors for antibiotic resistance: a systematic review. Clin. Infect. Dis. 32:1055-1061.
13. Hernández, J. R., A. Pascual, R. Cantón, L. Martinez-Martínez, and Grupo de Estudio de Infección Hospitalaria (GEIH). 2003. Escherichia coli y Klebsiella pneumoniae productores de betalactamasas de espectro extendido en hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm. Infecc. Microbiol. Clin. 21:77-82.
14. Hryniewicz, K., K. Szczypa, A. Sulikowska, K. Jankowski, K. Betlejewska, and W. Hryniewicz. 2001. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J. Antimicrob. Chemother. 47:773-780.
15. Lescure, F. X., M. Eveillard, Y. Douadi, and F. Eb. 2001. Community-acquired multiresistant bacteria: an emerging problem? J. Hosp. Infect. 49:149-151.
16. Manges, A. R., J. R. Johnson, B. Foxman, T. T. O'Bryan, K. E. Fullerton, and L. W. Riley. 2001. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N. Engl. J. Med. 345:1007-1013.
17. Martínez-Martínez, L., A. Pascual, M. D. C. Conejo, I. García, P. Joyanes, A. Domenech-Sanchez, and V. J. Benedi. 2002. Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Kebsiella pneumoniae and relationship to extended-spectrum beta-lactamase production. Antimicrob. Agents Chemother. 46:3926-3932.
18. Matthew, M., A. M. Harris, M. J. Marshall, and G. W. Ross. 1975. The use of analytical isoelectric focusing for detection and identification of beta-lactamases. J. Gen. Microbiol. 88:169-178.
19. McCabe, W. R., and G. G. Jackson. 1962. Gram-negative bacteremia. I. Etiology and ecology. Arch. Intern. Med. 110:847-855.
20. National Committee for Clinical Laboratory Standards. 2002. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard. NCCLS document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing, 12th informational supplement. NCCLS document M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pa.
22. Oliver, A., J. C. Perez-Diaz, T. M. Coque, F. Baquero, and R. Canton. 2001. Nucleotide sequence and characterization of a novel cefotaxime-hydrolyzing beta-lactamase (CTX-M-10). Antimicrob. Agents Chemother. 45:616-620.
23. Paterson, D. L., N. Singh, T. Gayowski, and I. R. Marino. 1999. Fatal infection due to extended-spectrum beta-lactamase producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis. Clin. Infect. Dis. 28:683-684.
24. Paterson, D. L. 2000. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin. Microbiol. Infect. 6:460-463.
25. Paterson, D. L., L. Mulazimoglu, J. M. Casellas, W. C. Ko, H. Goossens, A. Von Gottberg, S. Mohapatra, G. M. Trenholme, K. P. Klugman, J. G. McCormack, and V. L. Yu. 2000. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin. Infect. Dis. 30:473-478.
26. Paterson, D. L., W. C. Ko, A. Von Gotteberg, J. M. Casellas, L. Mulazimoglu, K. P. Klugman, R. A. Bonomo, L. B. Rice, J. G. McCormack, and V. L. Yu. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39:2206-2212.
27. Paterson, D. L. 2002. Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin. Infect. Dis. 34:1564-1567.
28. Pillay, T., D. G. Pillay, M. Adhikari, and A. W. Sturm. 1998. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates. Am. J. Perinatol. 15:47-51.
29. Rasheed, J. K., C. Jay, B. Metchock, F. Berkowitz, L. Weigel, J. Crellin, C. Steward, B. Hill, A. A. Medeiros, and F. C. Tenover. 1977. Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob. Agents Chemother. 41:647-653.
30. Simarro, E., F. Navarro, J. Ruiz, E. Miri, J. Gomez, and B. Mirellis. 2000. Salmonella enterica serovar Virchow with CTX-M-like beta-lactamase in Spain. J. Clin. Microbiol. 38:4676-4678.
31. Vila, J., M. A. Marcos, and M. T. Jiménez de Anta. 1996. A comparative study of different PCR-based DNA fingerprinting techniques for typing of the Acinetobacter calcoaceticus-A. baumannii complex, J. Med. Microbiol. 44:482-489.
32. Wiener, J., J. P. Quinn, P. A. Bradford, R. W. Goering, C. Nathan, K. Bush, and R. A. Weinstein. 1999. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 281:563-564.